DRG Epidemiology’s coverage of fibromyalgia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of fibromyalgia for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered.
DRG Epidemiology’s fibromyalgia forecast will answer the following questions:
Of all people with fibromyalgia, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with fibromyalgia, how many in each of the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of fibromyalgia over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following fibromyalgia subpopulations:
Diagnosed prevalent cases by drug-treatment status.
Total prevalent cases of fibromyalgia with comorbid anxiety.
Total prevalent cases of fibromyalgia with comorbid depression.
Total prevalent cases of fibromyalgia with comorbid migraines.
Total prevalent cases of fibromyalgia with comorbid insomnia.
Total Prevalence of Fibromyalgia per 1,000 People Aged 18+ in 2021 and 2041
Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Fibromyalgia Over the Next 20 Yearsttttttttt
Analysis of the Prevalent Cases of Fibromyalgia in 2021 by Diagnosed and Drug-Treated Statusttttttttt
Epidemiology Data
Methods
Total Prevalent Cases
Total Prevalent Cases by Comorbidity
Diagnosed Prevalent Cases of Fibromyalgia
Diagnosed Drug-Treated Prevalent Cases of Fibromyalgia
Reference Materials
Literature Review
Studies Included in the Analysis of Fibromyalgia
Studies Excluded from the Analysis of Fibromyalgia
Risk / Protective Factors
Risk / Protective Factors for Fibromyalgia
Bibliography
Abbreviations
Glossary
Natasha Nahar
Narendra Parihar, M.P.H., is a principal epidemiologist at Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.
